Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07467668 · ClinicalTrials.gov registry record · NA
Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure
A NA study, sponsored by Kaiser Permanente.
- Not yet
- Registry status
- NA
- Development phase
- 3,000
- Enrollment target
NCT07467668: Clinical Trial NA study, sponsored by Kaiser Permanente.
NCT07467668 is a NA study that has not yet begun recruiting, run by Kaiser Permanente. The registered enrollment target is 3,000 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (114% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07467668, a NA study, has not yet begun recruiting, sponsored by Kaiser Permanente.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
The INITIATE-HF study is a cluster randomized controlled trial that aims to find out if reminding doctors about treatment guidelines for iron deficiency in adults with heart failure who are hospitalized and have evidence of iron deficiency changes the subsequent use of intravenous (IV) iron. Two groups of hospitalized adult patients with known heart failure and iron deficiency will be compared: * Group 1 will include doctors who receive a notification with their patient's iron storage test results and guideline recommendations related to the use of IV iron. * Group 2 will include doctors who do not receive this notification and continue with usual standard of care. The study will measure if this provider-facing notification affects physician use of recommended IV iron treatment in eligible patients with heart failure, left ventricular ejection fraction less than 50%, and iron deficiency. Secondarily, if there is an increased use of IV iron observed in the intervention group, this study will evaluate whether there are differential health outcomes (i.e., fewer subsequent hospital visits and lower risk of death) of patients whose providers were assigned to the intervention group.
Primary Outcome
The primary outcome is the implementation outcome of the percentage of patients who receive IV iron within 7 days of hospitalization to determine how the provider-facing notification influences provider behavior and care processes.
Interventions
- OTHER Notification Group
- OTHER No Notification Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What is known before NCT07467668 opens enrollment
NCT07467668 is an interventional study that assigns participants to a tested intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (114% higher).
The record links to 0 conditions, and to 2 interventions - of which Notification Group is the first listed.
NCT07467668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07467668 about?
NCT07467668 is a clinical study titled "Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure". The INITIATE-HF study is a cluster randomized controlled trial that aims to find out if reminding doctors about treatment guidelines for iron deficiency in adults with heart failure who are hospitalized and have evidence of iron deficiency changes the subsequent use of intravenous (IV) iron. Two gr...
What is the current status of trial NCT07467668?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 3,000 participants. The study started on 2026-03-09. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07467668?
The interventions under investigation include: Notification Group (OTHER), No Notification Group (OTHER).
Who is sponsoring clinical trial NCT07467668?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07467668's enrollment target sits among peer trials
3,000 40th of 2000 higher than 1,959 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI